A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Shoji NagaoAi KogikuKazuhiro SuzukiTakashi ShibutaniKasumi YamamotoTomoatsu JimiMiho KitaiTakaya ShiozakiKazuko MatsuokaSatoshi YamaguchiPublished in: Journal of ovarian research (2020)
The combination chemotherapy with gemcitabine and bevacizumab was feasible, effective and safe. This combination chemotherapy may be explored in a further randomized trial.